Pregnant women with HIV infection can expect healthy survival: three-year follow-up.

Objectives: To document postpartum disease-free survival of HIV-infected women taking antiretroviral therapy (ART) during pregnancy.

Methods: Laboratory and clinical data were collected on all HIV-infected pregnant women delivering from 1998 to 2002 and followed up until September 2004 at 6 hospitals in London. Mothers were grouped according to receipt of zidovudine monotherapy (ZDVm), highly active antiretroviral therapy (HAART) given during and continued after pregnancy (cHAART), and short-term HAART given during pregnancy and discontinued on delivery (START).

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Objective: To assess the risks and benefits of administering highly active antiretroviral therapy (HAART) during the treatment of tuberculosis (TB) in HIV-infected patients.

Design And Methods: HIV-1 patients presenting to 12 HIV centres in Greater London and south-east England with culture-proven TB were identified from January 1996 to June 1999. Case-notes were reviewed retrospectively.